Kosuke Arita
Hokkaido University
Quality of lifeVitamin D and neurologyUrologyIntensive care medicineFemoral neckDenosumabOsteoporosisBone mineralBisphosphonateTeriparatideOsteonecrosis of the jawDiscontinuationRomosozumabFemur fracturePostmenopausal osteoporosisOrthopedic surgeryMedicine
1Publications
0Citations
Publications 2
Newest
#1Hotaka Ishizu (Hokkaido University)H-Index: 1
#2Kosuke Arita (Hokkaido University)
Last. Norimasa Iwasaki (Hokkaido University)H-Index: 45
view all 5 authors...
Introduction: Osteoporosis is characterized by the fragility of bones, leading to fractures and, consequently, the deterioration of functional capacity and quality of life. Postmenopausal women, in particular, are prone to osteoporosis and often require anti-osteoporosis treatment. In the last few decades, various anti-osteoporosis drugs have been approved for clinical use. In an aging society, osteoporosis cannot be treated using a single agent; therefore, switching therapy is an important trea...
Source
#1Tomohiro Shimizu (Hokkaido University)H-Index: 10
#2Kosuke Arita (Hokkaido University)
Last. Norimasa Iwasaki (Hokkaido University)H-Index: 45
view all 10 authors...
Purpose We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. Methods Postmenopausal osteoporosis patients with a high risk of fracture-154 in total-were recruited; their therapies were switched to ROMO or ...
Source